
|Articles|May 29, 2020
ASCRS 2020: Clinical trial results of KP1-121 0.25% for dry eye treatment
Author(s)Alex Delaney-Gesing
Advertisement
Edward Holland, MD, director of Cornea Services at Cincinnati Eye Institute, speaks with Ophthalmology Times' David Hutton on the results of a clinical trial using KP1-121 0.25% (loteprednol etabonate) for dry eye treatment during the 2020 ASCRS virtual meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
2
Dry Eye Awareness Month: building a strong optometry-ophthalmology co-management model
3
FDA grants priority review to Satralizumab sBLA for thyroid eye disease
4
REGENXBIO doses first patient in NAAVIGATE, phase 2b/3 sura-vec trial for diabetic retinopathy
5
























